HR and breast cancer: Also, according to the study by Goetz et al., the combination of abemaciclib and a nonsteroidal aromatase inhibitor get significantly better progression-free survival and objective response rate, making it an effective agent in the treatment of HR+, HER2− advanced breast cancer [10].